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ABSTRACT
Insulin-like factor 3 (INSL3) is a small peptide hormone made
and secreted uniquely by mature Leydig cells in the testes of all
mammals. Importantly, this expression and secretion appears to
be constitutive and therefore reflects the differentiation status
and number of the Leydig cells present, differing thereby from
testosterone, which is acutely and homeostatically regulated by
the hormones of the hypothalamic-pituitary-gonadal axis. As a
consequence, the measurement of INSL3 either as mRNA in the
testis or as secreted peptide circulating in the blood provides an
excellent assessment of Leydig cell differentiation, for example,
during fetal development, puberty, or aging or following
exposure to endocrine-disrupting agents. Whereas INSL3 is
proving increasingly useful as a biomarker for testis status, less is
known about its functions, particularly in the adult male.
Current evidence points to autocrine, paracrine, and endocrine
roles, acting through the G-protein-coupled receptor called
RXFP2, although more research is required to characterize these
functions in detail.
HPG axis, hypogonadism, INSL3, Leydig cell, puberty,
testosterone
INTRODUCTION
Insulin-like factor 3 (INSL3; formerly relaxin-like factor) is
a secreted peptide hormone that, in analogy to the structurally
related hormones relaxin or insulin, is presumed also to
conform to a heterodimeric A-B structure (Fig. 1) of
approximately 6 kDa once released from the producing cells
[1, 2]. Doubt is attached to this assumption because, first, both
the precursor pro-form (pro-INSL3) of approximately 14–18
kDa, which includes a connecting C-peptide domain, as well as
the mature A-B heterodimer, have been shown to be equally
bioactive [3] and second, at least in the pig, the longer pro-
INSL3 has been recently identified as a major circulating form
of the hormone [3], although also the mature shorter A-B
peptide is present in blood [4]. It appears that whereas the B-
domain comprises much of the receptor-binding site, it is
essential for activity that this is constrained within a specific
conformation by the cosynthesized A-domain [5, 6]. The C-
domain is part of the initial gene translation product and does
not appear to interfere with receptor binding or activation.
Inspection of Figure 1C shows that the C-domain does not in
fact occlude the region of the molecule assumed to interact
with its receptor via the amino acid side chains shown in red.
In all male mammals, INSL3 is a major secreted product of
the interstitial Leydig cells of the mature testes (Fig. 2F). In the
adult rat, depending on strain and age, INSL3 concentration in
peripheral blood is 1–10 ng/ml, whereas in the interstitial
lymph surrounding the Leydig cells it is recorded as being
;400 ng/ml [7]. INSL3 can also cross the blood-testis barrier
to be present in luminal fluid from seminiferous tubules, rete
testis, or epididymis at a concentration of 10–20 ng/ml [7]. The
evidently very high rate of synthesis and secretion is reflected
by quite intense immunohistochemical staining of the Leydig
cell cytoplasm in all species investigated. In some species
(mice, bovine), there is clear punctate accumulation of staining
in subcellular organelles, probably corresponding to the Golgi
[8] (Fig. 2F). From its gene sequence, with a characteristic
signal peptide, its secretory behavior, and the presence of furin-
like cleavage signals separating the peptide domains, INSL3
appears to be made in the classical secretory pathway.
However, typical dense-core secretory granules have been
only rarely observed in Leydig cells [9], suggesting that INSL3
might in fact be using a constitutive unregulated pathway for
secretion.
DIVERSE LEYDIG CELL POPULATIONS
In most species, there are two discrete populations of Leydig
cells. One population arises during fetal development shortly
after the expression of the SRY gene and the early
differentiation of the fetal testis from the gonadal ridge. These
cells produce INSL3, as well as androgens, essential for the
correct development of the male reproductive system [10].
Recent studies show that the fetal Leydig cells mostly make
androstenedione, which is converted by fetal Sertoli cells into
testosterone [11, 12]. Whereas testosterone appears to be
needed for the adequate development of Wolffian duct
derivatives and the external genitalia, INSL3 is essential for
the initial transabdominal phase of testicular descent, whereby
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it acts on the specific receptors, called RXFP2, in the
gubernacular ligaments linking the testes to the inguinal region
of the abdominal cavity. Under INSL3 influence, the
gubernacular bulbs thicken, effectively retaining the testes in
the lower abdomen while the rest of the body and its organs
grow away dorsally [13]. This first phase of testicular descent
occurs relatively early in gestation in some species (e.g.,
ruminants, humans) but is quite late in others, such as rodents,
where it is completed only at or after birth [14]. Correspond-
ingly, we find that INSL3 is secreted maximally already in the
first half of gestation in humans [15], whereas in rodents
maximal levels are observed only at term of pregnancy
(Anand-Ivell et al., unpublished). Little is known about the
regulation of the fetal Leydig cell population. Whereas in
humans at least some aspects of fetal Leydig cell regulation are
governed by luteinizing hormone (LH), in mice the differen-
tiation of fetal Leydig cells is independent of LH and rather
appears to make use of adrenocorticotropic hormone (ACTH)
[16]. We can use INSL3 to monitor this process, for example,
in the LH receptor knockout mouse [17; Ivell et al.,
unpublished] (Fig. 2), where there is no difference in INSL3
expression or Leydig cell density at birth in the LH receptor
knockout compared to the wild type. This is quite different for
the adult-type Leydig cell population, which also in mice is
absolutely dependent on LH secretion (Fig. 2).
In rodents, the fetal Leydig cell population appears to
involute mostly during the postnatal decline in gonadotropin
secretion, though fetal Leydig cells may still be evident on
appropriate immunohistochemical staining, for example, for
17bHSD-10 [18]. With the beginning of puberty, at around
Postnatal Days (PND) 10–13 in the rat, new Leydig cells
appear to differentiate and proliferate from resident peritubular
stem Leydig cells (SLC) to become progenitor Leydig cells
FIG. 2. Immunohistochemical identification of INSL3 epitopes in the testes of LH receptor knockout mice (A, B, D) or their wild-type siblings (C, E, F).
Testes were collected and processed either on Postnatal Day 1 to show fetal Leydig cells (A–C) or at 2 m (D–F) to illustrate the postpubertal testis.
Immunohistochemistry was as in Balvers et al. [8], using as primary antibody the rat polyclonal #63 at a dilution of 1:1000. Mature Leydig cells are
indicated by arrows; note the punctate appearance of the staining, suggesting retention of epitopes in the Golgi system. Negative controls (B and E) were
identical to the sections shown in A and F, respectively, except that the primary antibody was replaced by an equivalent concentration of preimmune
serum. Bar in F ¼ 100 lm.
FIG. 1. A) Diagrammatic scheme to show expression of the INSL3 gene,
first as a transitory prepro-form, including signal peptide (SP), which is
removed cotranslationally to generate pro-INSL3. This may then be
processed further to result in the A-B heterodimer. Predicted tertiary
structure of heterodimeric INSL3 (B) and of the INSL3 precursor (pro-
INSL3; C) based on the known conformation of the two-chain insulin-like
heterodimer [67]. The cysteine bridges holding the A- and B-domains in
their correct conformation are shown in yellow, and those amino acid side
groups involved in receptor interaction are shown in red.
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(PLC), eventually outnumbering any of the persisting fetal
Leydig cells. Following a proliferation phase, these new adult-
type Leydig cells undergo further differentiation, first at around
PND 28 in the rat, to immature Leydig cells (ILC), then later to
mature adult-type Leydig cells, a process that appears to be
completed by about 7–8 wk. This process can be monitored by
INSL3 expression, which has its first appearance in rats
relatively late at about Day 30.
In some species (e.g., humans), there appears to be an
intermediate population of Leydig cells manifest in the
immediate postnatal phase of infancy. These cells give rise to
the peak in testosterone production at 3–4 mo, referred to as the
‘‘minipuberty’’ [19]. The origin of these cells is obscure,
although there is some evidence to suggest that they may
actually represent an independent generation of Leydig cells
from resident stem cells [20, 21]. Whether these cells involute
again only to redifferentiate during puberty is not known. It
appears that the ‘‘minipuberty’’ is accompanied also by a burst
in INSL3 secretion into the blood [22]. Part of the confusion in
interpretation here is due to the fact that Leydig cells are
traditionally defined by their mature phenotype; if cells of that
description are not identifiable, they are considered to have
disappeared or died when in fact they may have only
dedifferentiated, for example, in the absence of gonadotropin
stimulation. Under normal circumstances, there are very few
observations of actual Leydig cell death or apoptosis in the
older testis. In rodents, our observation [23; Anand-Ivell and
Ivell, unpublished] is that the older Leydig cells (.12 mo
mice; .22 mo rats) appear smaller in diameter and show
reduced INSL3 expression and secretion, whereas the number
of these cells in the interstitium is similar to that in younger
animals. In the following sections, unless otherwise noted, we
refer to adult fully mature Leydig cells.
LACK OF ACUTE REGULATION
Leydig cells are experimentally convenient cells that have
been well characterized for their regulated secretion of
testosterone (or progesterone) under the acute influence of
LH, or equivalent cAMP-generating agents. Pulses of testos-
terone are released and/or their enzymatic synthesis is up-
regulated within minutes of LH stimulation, hence exhibiting
in vivo the well-known correspondence between testosterone
entering the circulation and LH pulsatility [24]. There appears
to be no such relationship in regard to INSL3 secretion and
synthesis. It seems that INSL3 is released from Leydig cells in
an unregulated fashion more or less as soon as it has been
made. As a consequence, there is a very good quantitative
association between INSL3 peptide measured in blood or
culture media or visualized by immunohistochemistry and the
INSL3 mRNA content of the Leydig cells [25–27].
CHRONIC REGULATION OF LEYDIG CELL FUNCTION
It is important to emphasize that the above regulation is
referring to short-term acute effects in the order of minutes or
hours only and must be clearly separated from chronic effects
occurring over several days or longer periods. Leydig cells are
highly adaptive cells whose differentiation status chronically
reflects the status of the hypothalamic-pituitary-gonadal (HPG)
axis and, in particular, LH. Thus, Leydig cells differentiate
during puberty largely under the influence of increased
amplitude and frequency of LH pulsatility [28]. This
differentiation is evident as massively increased specific gene
transcription on a per cell basis, by an increase in cytoplasmic
and nuclear size, by a concomitant increase in smooth
endoplasmic reticulum for steroidogenesis, and by the adoption
of a specific, mature adult-type Leydig cell morphology [29,
30]. Chronic down-regulation of the HPG axis, for example, by
chronic application of a gonadotropin-releasing hormone
(GnRH) antagonist [31], or steroidal male contraception [32],
or in seasonal breeders [33], causes Leydig cells to involute,
becoming effectively less differentiated. INSL3 expression
mirrors these changes. Thus, whereas Bay et al. [34] show no
effect of human chorionic gonadotropin (hCG) on peripheral
INSL3 concentration in hypogonadal patients after 72 and 96 h
of treatment, like Foresta et al. [35], they observed a large
effect after 1 or more months of treatment, by which time the
immature Leydig cells of the hypogonadal men have
differentiated under hCG influence.
INSL3 VERSUS TESTOSTERONE
For various reasons, testosterone is a complex parameter in
adult males of any species. Besides the issues surrounding its
bioavailability, leading to discussion as to whether total
testosterone, bioavailable testosterone, or so-called free
testosterone are the more meaningful parameters [36], the
steroid is generated and metabolized in a highly dynamic
manner, leading to high within-individual and diurnal fluctu-
ations, especially in mice [37]. Moreover, its synthesis is
regulated acutely (minutes and hours) by the hormones of the
HPG axis, primarily LH, acting on the steroidogenic enzymes
and steroid transport proteins, such as the steroidogenic acute
regulatory protein. This is a consequence of activation of
cAMP- and protein kinase A-dependent signaling pathways in
Leydig cells via the mediation of the LH receptor [38, 39]. This
in turn can be acutely desensitized by higher concentrations of
LH [40]. Most significant, the steroid produced by the Leydig
cells forms part of a negative feedback loop regulating the
production (pulse amplitude and frequency) of LH by the
pituitary. Together these mechanisms ensure an acutely
variable though, within a normal biological range, consistent
level of testosterone in the blood. In addition, in circumstances
where circulating testosterone is insufficient to trigger the
negative feedback loop controlling the HPG axis, testosterone
is also chronically influenced by the long-term differentiation
status of the Leydig cells. Thus, the measurement of
testosterone reflects effects at the hypothalamic, pituitary, and
testicular levels; it responds to both acute and chronic
physiology; and it can furthermore be influenced in its
biological relevance by the concomitant variations in binding
proteins and its metabolism in target organs.
In marked contrast to the above, INSL3 is constitutively
expressed by the Leydig cells, is not acutely regulated by the
hormones of the HPG axis, and in healthy individuals shows
minimal diurnal or within-individual fluctuation, even over
several weeks or months [2]. Thus, unlike testosterone, INSL3
provides a less ambiguous measure of Leydig cell functionality
(i.e., a combination of Leydig cell differentiation status and the
absolute numbers of Leydig cells in the testes). The best
supporting evidence for this was provided by the FAMAS
(Florey Adelaide Male Aging Study) study of nearly 1200
Australian men [41]. First, it could be shown that among men
who have had one testis removed (uniorchid) and presumably
about half the number of Leydig cells compared to normal
intact men (with both testes), INSL3 levels were significantly
lower than in the intact control group, unlike testosterone levels
that did not significantly differ, largely due to the acute
compensation by the HPG axis [41]. Second, in the same group
of uniorchid men, there was a significant negative correlation
between circulating LH and INSL3, reflecting that under
conditions where testosterone production is likely to be rate
INSL3 AS A BIOMARKER OF LEYDIG CELL FUNCTIONALITY
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limiting, testes with lower Leydig cell functionality will have
low INSL3 but induce high LH as part of the HPG homeostatic
mechanism to elevate testosterone. This contrasts with what is
observed in intact men, where INSL3 correlates positively with
LH [34, 41]. Finally, this study revealed that there is a steady
12% per decade reduction in circulating INSL3 between the
ages of 40 and 80, whereas for testosterone, the equivalent
reduction is only 6% per decade, again due to compensatory
control by LH, which significantly increases over this period
[41].
INSL3 DURING PUBERTY
In rodents, shortly after birth there are still some persistent
fetal Leydig cells that appear to be expressing INSL3, though
these cells are not regulated by LH (Fig. 2). As the testes start
to grow, the fetal Leydig cells either involute or are simply
outnumbered by the proliferation of the new adult-type Leydig
cell pool from small peritubular mesenchymal stem cells
(SLC). In the rat or mouse, INSL3 is considered a relatively
late marker of Leydig cell differentiation, mRNA and protein
being first apparent at about PND 30 (rat) or PND 20 (mouse),
that is, in the so-called ILC [8, 27, 42]. Both mRNA and
protein (determined immunohistochemically) then increase to
reach a maximum at about PND 40–45 (rat) or PND 35
(mouse). When we look at the concentration of INSL3
circulating in the blood, this initially parallels the mRNA
levels within the testes [7, 27], suggesting again that it is more
or less constitutively secreted as soon as it is synthesized. Then,
at least in the rat, circulating INSL3 concentration rises
dramatically to reach a maximum at around PND 42 but
thereafter declines to attain a reduced adult steady state that
then persists [7, 27]. This is not the case for testosterone
measured in the same samples, which reaches its maximum
also at or shortly after PND 42 but then remains relatively
constant through early adulthood. The ‘‘overshoot effect’’ seen
for INSL3 is what one would expect if, during puberty, LH
pulses increase in amplitude and frequency until Leydig cells
have attained an advanced differentiation status but then
become reduced in intensity once that status is reached and
testosterone synthesis can be maintained by the acute
homeostatic actions of the HPG axis. This implies that after
puberty, Leydig cells may attenuate somewhat their differen-
tiation status and activity, a change that is directly reflected by
the circulating INSL3 concentration. This picture is inevitably
oversimplified since it takes no account of other steroids
generated by Leydig cells, for example, the large amounts of
androsterone, 3alpha-DIOL, or DHT, produced by PLC and
ILC [43] or the relative expression levels of the key enzymes
involved. We only know that by about 8–10 wk, Leydig cells
have stabilized in their phenotype, consistent with a matured
HPG axis [44].
The close relationship between INSL3 secretion and Leydig
cell functionality and the relatively small within-individual
variance in circulating INSL3 values have made this an ideal
parameter with which to assess factors such as maternal
endocrine disruptors on Leydig cell differentiation. Recently,
we have been able to show that maternal exposure to
diethylstilbestrol or to dibutylphthalate significantly alters the
adult-type Leydig cell differentiation trajectory, either sub-
stance causing an advance in puberty, largely by modulating
the trade-off between Leydig cell proliferation and differenti-
ation [27]. This study during normal rat puberty yielded very
similar results to a previous study using the ethane dimethyl-
sulfonate rat model of adult-type Leydig cell differentiation
[26] where circulating INSL3 showed that the trajectory of new
Leydig cell differentiation in this model is kinetically very
comparable to that during puberty [27].
In human puberty, the situation appears to be less clear in
that, while circulating INSL3 concentrations increase as
expected, by Tanner stage 5 they appear still not to have
attained by some large margin the concentrations observed in
young adulthood [45, 46]. This would imply that there is still
substantial development of the Leydig cells in young men
subsequent to reaching Tanner stage 5 at around 15–17 yr of
age.
INSL3 AND AGING
The FAMAS cross-sectional study showed that INSL3
declines gradually with age (12% per decade) from early
adulthood on [41], presumably reflecting the functional
capacity of the Leydig cells. This decline also corresponded
to the lesser decline in testosterone as well as the change in
Leydig cell functional capacity as measured by the testoster-
one/LH ratio [41]. Significantly, more detailed analysis of this
cross-sectional study showed that INSL3 was a robust
parameter showing an inverse relationship to smoking (unlike
testosterone) and was otherwise a useful predictor of metabolic
syndrome [47]. Histological examination of aging human testes
[48] suggests that there is both a loss of Leydig cells with age
and a reduction in differentiation status (cells are smaller and
less morphologically differentiated), presumably concomitant
with loss of LH sensitivity [49]. This is comparable to what has
been observed in old rats [7, 23], where INSL3 expression also
appears to be down-regulated with age. The FAMAS study
showed that even among young healthy men there is a broad
range of INSL3 expression (0.5–1.5 ng/ml); this range is
maintained as men age [41]. What will be particularly
interesting is to identify other features that are associated with
the progressively increasing proportion of aging men with low
(,0.5 ng/ml) circulating INSL3. In this context, it is interesting
to note that INSL3 has recently been shown to be associated
with bone metabolism and that people with an inactivating
mutation in their INSL3 receptor, RXFP2, have significant
osteopenia [50], as do INSL3 knockout mice [50]. Taken
together, such results suggest that INSL3 could become a very
useful parameter in the differential diagnosis of conditions such
as late-onset hypogonadism.
SEASONAL BREEDING AND INSL3
Seasonal breeding mammals offer an excellent model with
which to study in a controllable fashion the differentiation
events otherwise associated only with puberty. In male
mammals such as deer or hamsters, changing day length is
accompanied by a long-term annual cycle of attenuation of the
HPG axis, followed by a renewed puberty-like reactivation of
the hypothalamic and pituitary hormones [51]. This is
accompanied by behavioral and physical changes to accom-
modate and synchronize seasonally restricted breeding activity.
During the attenuation phase, LH and follicle-stimulating
hormone production is minimal, and consequently both
spermatogenesis and steroidogenesis and hence also testicular
size are all drastically reduced. Histologically, during this
attenuation phase, there appears to be an involution of the
Leydig cells, which become small and indistinct. In deer,
measurement of INSL3 at the mRNA level and at the
immunohistochemical level shows that this does not appear
to be due to a loss or apoptosis of Leydig cells [33]; rather,
these seem to dedifferentiate into small peritubular fibroblast-
like cells, not very different from prepubertal Leydig stem cells
(SLC). Presumably, these cells will redifferentiate again once
IVELL ET AL.
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the hormones of the HPG axis are reactivated at the beginning
of the next breeding season. Similar observations have been
made in the laboratory hamster subjected to alternating short-
or long-day lighting regimes (Ivell et al., unpublished; Fig. 3,
A–C). Here it is interesting to note that in this species there is
also specific INSL3 immunostaining within the seminiferous
compartment in elongating spermatids (Fig. 3B). Whether this
is because of local synthesis uniquely in spermatids in this
species or, less likely, whether this represents an accumulation
of INSL3 into the seminiferous compartment sequestered by
RXFP2 on the germ cells, possibly at a time before the Sertoli
cell tight junctions of the blood-testis barrier are established
[52], is not known. In the sheep, where testicular seasonality
though not seasonal breeding is less pronounced, there appears
to be less morphological involution of the Leydig cells (Ivell et
al., unpublished; Fig. 3). In this figure, this can be seen both at
the beginning of puberty (cf. Fig. 3, E and F), where there is a
clear population of unstained Leydig cell precursors (arrow-
heads) in addition to residual fetal Leydig cells, as well as in
the transition from long day (July; Fig. 3J) to short day
(January; Fig. 3L), where both unstained and INSL3-stained
interstitial cells are clearly evident. Given the new molecular
tools available with which to assess INSL3 expression, it will
be interesting to take a more detailed look at this unusual cycle
of Leydig cell differentiation, involution, and redifferentiation
and its obvious relevance in the context of revitalizing Leydig
cell functional capacity in the aging male.
INTRATESTICULAR FUNCTION OF INSL3
While the focus here has been primarily on the role of
INSL3 as a biomarker of Leydig cell functional capacity, it is
also important to understand the possible roles of INSL3 within
the testis. The main functions of INSL3 appear to be to induce
the first phase of testicular descent during fetal development
[53, 54] or to modulate follicle development during the estrous
cycle in female mammals [55]. Recently, an additional
endocrine role for INSL3 has emerged with the discovery of
marked activity in regard to osteoclast function and bone
remodeling [50, 56]. Moreover, RXFP2-linked quantitative
trait loci appear to be associated with horn growth in sheep [57]
and cows [58]. Within the testis, the specific receptors for
INSL3, called RXFP2, are expressed on both meiotic and
postmeiotic germ cells within the seminiferous tubules as well
as in a much lower amount on the Leydig cells themselves,
suggesting both paracrine and autocrine roles [59]. Supporting
FIG. 3. Application of INSL3 immunohistochemistry to the testes of seasonally breeding mammals. A) Adult hamster (transferred to short days,
nonbreeding). B) Adult hamster (long day, breeding); note that besides the Leydig cells (arrows), also the elongating spermatids stain positively for INSL3
epitopes in this species. C) As in B but using pre-immune serum. D–L) Sheep testes from birth through puberty to adulthood. D, day 1; E, 2 wk; F, 4 wk; G,
6 wk; H, 4 mo; I, 5 mo; J, 6 mo (July, breeding seasons); K, as J, but using preimmune serum as negative control; L, 12 mo (January, nonbreeding season).
Note particularly in E–G and L the many unstained Leydig cell precursors in the interstitium (arrowheads). Immunostaining in the hamster employed the
rat polyclonal antiserum #63 [8], while for the sheep testes, the rabbit polyclonal #33 [68] was used. The protocol was as in Balvers et al. [8]. Bars in C
and K ¼ 100 lm.
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the former, Kawamura et al. [60] showed that INSL3 protected
germ cells against apoptosis on treatment with a GnRH agonist,
and Del Borgo et al. [61] showed that intratesticular injection
of an INSL3 antagonist led to substantial germ cell loss,
together pointing to an antiapoptotic function of INSL3.
Moreover, in a clinical study assessing the consequences of a
steroidal contraceptive regimen in men, it was shown that
specific germ cell loss was more effective in men who had
lower circulating INSL3 concentrations [62]. Supporting this
concept, we were able to show that INSL3 is indeed able to
cross the established blood-testis barrier in adult rats from the
interstitium to the seminiferous compartment in sufficient
amounts to be able to activate receptors there [7]. Conventional
knockout mice for either the INSL3 gene or that of its receptor,
RXFP2, have proved difficult to assess because the primary
phenotype of such male mice is cryptorchidism, which itself is
highly deleterious to spermatogenesis. Attempts to correct this
cryptorchidism surgically suggest no major phenotypic differ-
ence in the adult testis [53]. Recently, a conditional RXFP2
knockout mouse has been generated using Cre-LoxP technol-
ogy, wherein the RXFP2 gene has been specifically deleted in
late male germ cells only, thus avoiding cryptorchidism and its
consequences [63]. Although this mouse has been assessed
only after attainment of sexual maturity, initial observations
suggest that the RXFP2 expressed in these germ cells, at least
in the mouse in early adulthood, is dispensable for male
fertility [63]. However, more studies are required to look at
effects at younger or older ages or under proapoptotic insult.
RXFP2 is also expressed at a low level on Leydig cells [59],
and it has been recently shown that when Leydig cells are
cultured at a very reduced cell density, such that endogenously
produced INSL3 is also at a low concentration in the medium,
added INSL3 is significantly able to induce steroidogenesis
[64]. No such effects are evident when Leydig cells are
cultured at high concentration [59]. This result is comparable to
recent observations using the female equivalent of Leydig cells,
the theca interna cells of ovarian follicles. Here added INSL3 is
able, via RXFP2, to induce increased androgen production
[65]. The RXFP2 receptor appears to act via adenylyl cyclase
to raise the intracellular levels of cAMP [66], thus acting in a
similar way to LH. Now, in the adult testis, there are already
very high concentrations (;400 ng/ml) of INSL3 present in the
interstitial compartment [7]. It is therefore very unlikely that
endogenous INSL3 will be physiologically relevant for adult
Leydig cells in the sexually mature testis, which are likely
either to have their RXFP2 receptors desensitized or to be
anyway sufficiently activated in terms of cAMP by pituitary
LH. The situation may be quite different early in puberty
during the first spermatogenic wave, when LH is not yet
available in substantial amounts and when initial INSL3
secretion could be quantitatively quite relevant. This could also
be true for RXFP2 receptors on germ cells since early in
puberty the blood-testis barrier is not yet fully established and
even low interstitial concentrations of INSL3 could reach the
seminiferous compartment quite easily.
CONCLUSIONS
INSL3 is a major secretory product of phenotypically
mature Leydig cells. Moreover, because it appears to be
expressed in the constitutive pathway, its secretion into the
testicular interstitial space and hence into the bloodstream
largely reflects INSL3 gene expression and the differentiation
status of the Leydig cells as well as their absolute number. This
constitutive nonpulsatile expression gives INSL3 a great
advantage over testosterone as a parameter since, unlike the
latter, it is not acutely regulated by the hormones of the HPG
axis and thus shows relatively low within-individual variation
over quite long periods. For these reasons, we have found
INSL3 measurement to accurately reflect the dynamics of
Leydig cell differentiation and proliferation in situations such
as puberty, aging, or endocrine disruption.
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